Real Estate
Live Price
Offline$18.12
+0.39% today
1Y Change
+0.75%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sabra Health Care REIT, Inc. (SBRA) is a Real Estate stock with a market cap of $5.13B and listed on NASDAQ. The stock last traded around $18.12 and up 0.8% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +10.2%, EPS growth of +18.5%, a dividend yield of 5.9%. What stands out right now is revenue +10.2%, EPS +18.5%, free cash flow +12.3% with operating margin 29.0% and ROIC 34.3%. The dividend matters to the case here, with a current yield around 5.9%. Valuation already assumes a fairly strong business story at P/E 32.9 and price/sales 6.3. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines SBRA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Real Estate peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SBRA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SBRA Max Drawdown
-16.65%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SBRA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$569.5M
-8.8% YoY
FY Net Income
-$113.3M
-45.9% YoY
Free Cash Flow
$322.8M
+2.2% YoY
Revenue Growth
+10.2%
EPS Growth
+18.5%
Gross Margin
63.5%
Net Margin
19.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 775M | 703M | 648M | 625M | 570M |
| Gross Profit | 504M | 476M | 452M | 462M | 428M |
| Operating Income | 264M | 257M | 222M | 235M | 211M |
| EBITDA | 457M | 413M | 312M | 217M | 166M |
| Net Income | 156M | 127M | 14M | -78M | -113M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 72M | 60M | 41M | 49M | 112M |
| Total Assets | 5.5B | 5.3B | 5.4B | 5.7B | 6.0B |
| Total Liabilities | 2.7B | 2.6B | 2.6B | 2.7B | 2.6B |
| Shareholder Equity | 2.8B | 2.7B | 2.8B | 3.1B | 3.4B |
| Total Debt | 2.6B | 2.4B | 2.4B | 2.5B | 2.4B |
| Net Debt | 2.5B | 2.4B | 2.4B | 2.5B | 2.3B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
356M
+12.9% YoY
Capital Expenditures
34M
Free Cash Flow
323M
+2.2% YoY
Key ratios
Gross Margin
63.5%
Operating Margin
29.0%
Net Margin
19.2%
ROE
5.6%
Debt / Equity
0.96x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.